Abivax Announces Submission of Financial Reports to French and U.S. Regulatory Agencies

PARIS, France, April 5, 2024 – Abivax SA, a pivotal player in the biotechnology industry, focused on the development of treatments for chronic inflammatory diseases, declared the completion of its essential financial documentation submissions. The company has successfully filed its Universal Registration Document with the Autorité des Marchés Financiers (AMF) in France and its Annual Report with the U.S. Securities and Exchange Commission (SEC) as of April 5, 2024.

The Universal Registration Document encompasses the annual financial report for 2023, the management and corporate governance report, and assessments from statutory auditors. These documents are now accessible for public review on Abivax's website, as well as on the AMF and SEC websites.

Following this announcement, Abivax communicated plans to conduct a webcast detailing the financial outcomes of 2023. Scheduled for April 8, 2024, the presentation aims to cover the company’s achievements over the past year and outline future projects. This session will also include a live Q&A, encouraging participant interaction.